Finkas Lindsay K, Ramesh Navneet, Block Lawrence S, Yu Bing Q, Lee Mei-Tsung, Lu Meng, Skarbinski Jacek, Iribarren Carlos
Kaiser Permanente San Rafael Medical Center, San Rafael, CA, USA.
Kaiser Permanente Oakland Medical Center, Oakland, CA, USA.
J Asthma Allergy. 2023 Sep 26;16:1041-1051. doi: 10.2147/JAA.S418144. eCollection 2023.
Previous studies on the outcomes of asthma and COVID-19 have shown inconsistent results. This study aimed to elucidate the association between asthma and COVID-19 outcomes.
We conducted a prospective study with a large health plan to compare the incidence of COVID-19 infection, hospitalization and ICU admission in a cohort of 41,282 patients with asthma and a 1:1 age-, sex-, and race-ethnicity-matched cohort without asthma across the following pandemic periods: pre-Delta (03/01/2020 to 05/31/2021), Delta (06/01/2021 to 12/31/2021), and Omicron (01/01/2022 to 08/13/2022). Demographic factors, comorbidities, COVID-19 test results, inpatient utilization, and COVID-19 vaccination status were collected from electronic health records.
Subjects with asthma were more likely than controls to undergo COVID-19 testing during the three pandemic periods and were less likely to test positive in the Omicron period (fully adjusted odds ratio=0.92; 95% CI=0.86-0.98; p=0.01). Relative to controls, patients with asthma had an increased risk of hospitalization for COVID-19 (fully adjusted hazard ratio=1.33; 95% CI=1.08-1.64; p=0.01) and borderline significant (p=0.05) higher rates of ICU admissions in the pre-delta period but not during the delta or Omicron periods. The increased risk of COVID-19 hospitalization associated with asthma was more pronounced in patients with severe asthma and in women compared with men. None of the associations were significantly modified by vaccination status.
Asthma was associated with a lower risk of COVID-19 infection but only during the Omicron period. Asthma was an independent risk factor for hospitalization for COVID-19 in the pre-delta period and this association was stronger for severe asthma and in women.
先前关于哮喘与新冠病毒病(COVID-19)结局的研究结果并不一致。本研究旨在阐明哮喘与COVID-19结局之间的关联。
我们对一个大型医疗保健计划进行了一项前瞻性研究,以比较41282例哮喘患者队列与年龄、性别和种族匹配的无哮喘队列在以下大流行期间COVID-19感染、住院和重症监护病房(ICU)入院的发生率:德尔塔变异株出现前(2020年3月1日至2021年5月31日)、德尔塔变异株时期(2021年6月1日至2021年12月31日)和奥密克戎变异株时期(2022年1月1日至2022年8月13日)。从电子健康记录中收集人口统计学因素、合并症、COVID-19检测结果、住院使用情况和COVID-19疫苗接种状况。
在三个大流行期间,哮喘患者比对照组更有可能接受COVID-19检测,且在奥密克戎变异株时期检测呈阳性的可能性较小(完全调整优势比=0.92;95%置信区间=0.86-0.98;p=0.01)。与对照组相比,哮喘患者因COVID-19住院的风险增加(完全调整风险比=1.33;95%置信区间=1.08-1.64;p=0.01),在德尔塔变异株出现前时期ICU入院率略高(p=0.05),但在德尔塔变异株或奥密克戎变异株时期没有这种情况。与哮喘相关的COVID-19住院风险增加在重度哮喘患者和女性中比男性更明显。疫苗接种状况对这些关联均无显著影响。
哮喘与较低的COVID-19感染风险相关,但仅在奥密克戎变异株时期。在德尔塔变异株出现前时期,哮喘是COVID-19住院的独立危险因素,这种关联在重度哮喘患者和女性中更强。